Company intelligence / Profile preview

PHARMAQ

Ownership: Private
Employees: ~420
Development stage: Commercial

Overview

PHARMAQ leads the global market for vaccines and health products targeting the aquaculture industry. Its portfolio includes commercialized vaccines such as AlphaJect® and next-generation parasiticides. The company’s R&D pipeline features new vaccines expected to launch soon in major markets like Norway, Chile, and the UK. Clinical results are focused on efficacy against key infectious diseases impacting farmed fish populations.

Therapeutic areas: Infectious Diseases
Modalities: VaccineBiologicSmall molecule
Industry: Veterinary

Drug pipeline

2 assets

AlphaJect

Commercial

Indications: Fish diseases

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on PHARMAQ.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PHARMAQ.

Explore the full profile